The Interrelationship between Sarcoidosis and Atherosclerosis—Complex Yet Rational

Hoss, Sara; Grinberg, Tzlil; Eisen, Ami

doi:10.3390/jcm11020433

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there are conflicting results between studies, there is research that provides empirical evidence linking a greater risk of STEMI and a diagnosis of sarcoidosis [ 6 – 8 ]. It has been hypothesised that the elevated risk of STEMI in this cohort can be attributed to the alterations in lipid metabolism seen in sarcoidosis, as well as the inflammatory nature of the disease, which both lead to an increased the risk of atherosclerosis [ 9 , 10 ]. However, to our knowledge there are currently no data available on how the presentation, impact, and outcome of STEMI differs in patients with sarcoidosis versus the general population.…”

Section: Introductionmentioning

confidence: 99%

Characteristics and clinical outcomes of patients with Sarcoidosis admitted for ST-elevation myocardial infarction in the United States: A propensity matched analysis from the National Inpatient Sample

Ahmed,

Najam,

Ramphul

et al. 2024

Arch Med Sci Atheroscler Dis

View full text Add to dashboard Cite

IntroductionSarcoidosis is a systemic inflammatory disorder characterised by non-caseating granulomas. Cardiac sarcoidosis (CS) normally causes conduction abnormalities, ventricular arrhythmias, and heart failure. Little is known about the characteristics and impact of sarcoidosis in patients admitted with ST-elevation myocardial infarction (STEMI). This study aims to fill this void.Material and methodsUtilising the National Inpatient Sample (NIS) database (2016–2020), individuals with STEMI were identified and categorised based on sarcoidosis presence whilst adjusting for confounders via logistic regression models.ResultsAmong 851,290 STEMI patients, 1215 had sarcoidosis. Before propensity matching, sarcoidosis patients were notably different in demographics and comorbidities compared to non-sarcoidosis patients. After propensity score matching (PSM), sarcoidosis patients were found to have a higher incidence of supraventricular tachycardia (SVT) (2.5% vs. 1.3%, p = 0.024) and acute kidney injury (AKI) (23.3% vs. 20.8%, aOR = 1.269, 95% CI: 1.02–1.58, p = 0.033) but a lower incidence of undergoing coronary artery bypass graft (CABG) (5.5% vs. 8.5%, aOR = 0.663; 95% CI: 0.472–0.931, p = 0.018), while no significant disparities were noted in PCI, cardiogenic shock, mortality, or mean length of stay (LOS).ConclusionsUsing propensity-matched large real-world data of STEMI patients, sarcoidosis was associated with fewer cases of CABG and a greater incidence of AKI and SVT compared to non-sarcoidosis patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Characteristics and clinical outcomes of patients with Sarcoidosis admitted for ST-elevation myocardial infarction in the United States: A propensity matched analysis from the National Inpatient Sample

Ahmed,

Najam,

Ramphul

et al. 2024

Arch Med Sci Atheroscler Dis

View full text Add to dashboard Cite

show abstract

Cardiovascular magnetic resonance in autoimmune rheumatic diseases: a clinical consensus document by the European Association of Cardiovascular Imaging

Mavrogeni

Pepe

Nijveldt

et al. 2022

European Heart Journal - Cardiovascular Imaging

View full text Add to dashboard Cite

Autoimmune rheumatic diseases (ARDs) involve multiple organs including the heart and vasculature. Despite novel treatments, patients with ARDs still experience a reduced life expectancy, partly caused by the higher prevalence of cardiovascular disease (CVD). This includes CV inflammation, rhythm disturbances, perfusion abnormalities (ischaemia/infarction), dysregulation of vasoreactivity, myocardial fibrosis, coagulation abnormalities, pulmonary hypertension, valvular disease, and side-effects of immunomodulatory therapy. Currently, the evaluation of CV involvement in patients with ARDs is based on the assessment of cardiac symptoms, coupled with electrocardiography, blood testing, and echocardiography. However, CVD may not become overt until late in the course of the disease, thus potentially limiting the therapeutic window for intervention. More recently, cardiovascular magnetic resonance (CMR) has allowed for the early identification of pathophysiologic structural/functional alterations that take place before the onset of clinically overt CVD. CMR allows for detailed evaluation of biventricular function together with tissue characterization of vessels/myocardium in the same examination, yielding a reliable assessment of disease activity that might not be mirrored by blood biomarkers and other imaging modalities. Therefore, CMR provides diagnostic information that enables timely clinical decision-making and facilitates the tailoring of treatment to individual patients. Here we review the role of CMR in the early and accurate diagnosis of CVD in patients with ARDs compared with other non-invasive imaging modalities. Furthermore, we present a consensus-based decision algorithm for when a CMR study could be considered in patients with ARDs, together with a standardized study protocol. Lastly, we discuss the clinical implications of findings from a CMR examination.

show abstract

The Interrelationship between Sarcoidosis and Atherosclerosis—Complex Yet Rational

Abstract: Sarcoidosis is a systemic inflammatory disease of unknown etiology, characterized by the presence of non-caseating granulomas in affected organs [...]

Cited by 2 publications

References 17 publications

Characteristics and clinical outcomes of patients with Sarcoidosis admitted for ST-elevation myocardial infarction in the United States: A propensity matched analysis from the National Inpatient Sample

Characteristics and clinical outcomes of patients with Sarcoidosis admitted for ST-elevation myocardial infarction in the United States: A propensity matched analysis from the National Inpatient Sample

Cardiovascular magnetic resonance in autoimmune rheumatic diseases: a clinical consensus document by the European Association of Cardiovascular Imaging

Contact Info

Product

Resources

About